|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: UST |
Gene summary for UST |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | UST | Gene ID | 10090 |
| Gene name | uronyl 2-sulfotransferase | |
| Gene Alias | 2OST | |
| Cytomap | 6q25.1 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | Q9Y2C2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10090 | UST | CCI_1 | Human | Cervix | CC | 4.60e-04 | 5.02e-01 | 0.528 |
| 10090 | UST | CCI_2 | Human | Cervix | CC | 1.25e-18 | 1.50e+00 | 0.5249 |
| 10090 | UST | CCI_3 | Human | Cervix | CC | 8.49e-04 | 3.10e-01 | 0.516 |
| 10090 | UST | HTA11_7696_3000711011 | Human | Colorectum | AD | 5.11e-07 | 2.72e-01 | 0.0674 |
| 10090 | UST | HTA11_99999970781_79442 | Human | Colorectum | MSS | 4.49e-35 | 6.73e-01 | 0.294 |
| 10090 | UST | A015-C-005 | Human | Colorectum | FAP | 6.68e-04 | 3.43e-01 | -0.0336 |
| 10090 | UST | HCC1 | Human | Liver | HCC | 3.29e-07 | 5.30e-01 | 0.5336 |
| 10090 | UST | HCC2 | Human | Liver | HCC | 2.08e-08 | 6.33e-01 | 0.5341 |
| 10090 | UST | HCC5 | Human | Liver | HCC | 5.72e-12 | 6.62e-01 | 0.4932 |
| 10090 | UST | RNA-P10T2-P10T2-3 | Human | Lung | AAH | 3.74e-02 | 8.36e-01 | -0.1408 |
| 10090 | UST | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 2.62e-19 | 7.94e-01 | -0.2116 |
| 10090 | UST | RNA-P25T1-P25T1-2 | Human | Lung | AIS | 3.11e-08 | 8.18e-01 | -0.1941 |
| 10090 | UST | RNA-P25T1-P25T1-3 | Human | Lung | AIS | 8.91e-16 | 9.61e-01 | -0.2107 |
| 10090 | UST | RNA-P25T1-P25T1-4 | Human | Lung | AIS | 5.15e-12 | 7.42e-01 | -0.2119 |
| 10090 | UST | RNA-P5T2-P5T2-1 | Human | Lung | MIAC | 3.63e-03 | 1.31e+00 | -0.0135 |
| 10090 | UST | RNA-P5T2-P5T2-3 | Human | Lung | MIAC | 1.56e-03 | 1.41e+00 | 0.0176 |
| 10090 | UST | RNA-P6T1-P6T1-1 | Human | Lung | MIAC | 3.31e-03 | 8.94e-01 | -0.0238 |
| 10090 | UST | RNA-P6T1-P6T1-3 | Human | Lung | MIAC | 4.62e-06 | 9.97e-01 | -0.0296 |
| 10090 | UST | RNA-P6T1-P6T1-4 | Human | Lung | MIAC | 3.17e-07 | 9.49e-01 | -0.0263 |
| 10090 | UST | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 7.06e-24 | 7.47e-01 | -0.0166 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00071639 | Cervix | CC | establishment or maintenance of cell polarity | 63/2311 | 218/18723 | 4.25e-11 | 8.76e-09 | 63 |
| GO:00300108 | Cervix | CC | establishment of cell polarity | 42/2311 | 143/18723 | 4.30e-08 | 2.62e-06 | 42 |
| GO:00109757 | Cervix | CC | regulation of neuron projection development | 88/2311 | 445/18723 | 4.26e-06 | 1.09e-04 | 88 |
| GO:00615647 | Cervix | CC | axon development | 89/2311 | 467/18723 | 1.71e-05 | 3.27e-04 | 89 |
| GO:00074097 | Cervix | CC | axonogenesis | 78/2311 | 418/18723 | 1.14e-04 | 1.43e-03 | 78 |
| GO:00507705 | Cervix | CC | regulation of axonogenesis | 34/2311 | 154/18723 | 4.87e-04 | 4.76e-03 | 34 |
| GO:0007163 | Colorectum | AD | establishment or maintenance of cell polarity | 77/3918 | 218/18723 | 5.72e-07 | 2.08e-05 | 77 |
| GO:0010975 | Colorectum | AD | regulation of neuron projection development | 129/3918 | 445/18723 | 2.88e-05 | 5.37e-04 | 129 |
| GO:0007409 | Colorectum | AD | axonogenesis | 122/3918 | 418/18723 | 3.36e-05 | 6.15e-04 | 122 |
| GO:0006790 | Colorectum | AD | sulfur compound metabolic process | 101/3918 | 339/18723 | 6.46e-05 | 1.07e-03 | 101 |
| GO:0030010 | Colorectum | AD | establishment of cell polarity | 50/3918 | 143/18723 | 6.90e-05 | 1.11e-03 | 50 |
| GO:0061564 | Colorectum | AD | axon development | 132/3918 | 467/18723 | 8.40e-05 | 1.31e-03 | 132 |
| GO:0050770 | Colorectum | AD | regulation of axonogenesis | 49/3918 | 154/18723 | 9.88e-04 | 9.28e-03 | 49 |
| GO:00071632 | Colorectum | MSS | establishment or maintenance of cell polarity | 72/3467 | 218/18723 | 1.90e-07 | 8.30e-06 | 72 |
| GO:00300102 | Colorectum | MSS | establishment of cell polarity | 47/3467 | 143/18723 | 2.74e-05 | 5.58e-04 | 47 |
| GO:00109752 | Colorectum | MSS | regulation of neuron projection development | 115/3467 | 445/18723 | 6.91e-05 | 1.20e-03 | 115 |
| GO:00074092 | Colorectum | MSS | axonogenesis | 105/3467 | 418/18723 | 4.32e-04 | 5.23e-03 | 105 |
| GO:00615642 | Colorectum | MSS | axon development | 115/3467 | 467/18723 | 5.33e-04 | 6.00e-03 | 115 |
| GO:00067902 | Colorectum | MSS | sulfur compound metabolic process | 85/3467 | 339/18723 | 1.52e-03 | 1.39e-02 | 85 |
| GO:00507701 | Colorectum | MSS | regulation of axonogenesis | 43/3467 | 154/18723 | 2.69e-03 | 2.12e-02 | 43 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| UST | SNV | Missense_Mutation | rs370216214 | c.1078N>T | p.Arg360Cys | p.R360C | Q9Y2C2 | protein_coding | deleterious(0.01) | possibly_damaging(0.719) | TCGA-A2-A0ET-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
| UST | SNV | Missense_Mutation | c.1099C>T | p.His367Tyr | p.H367Y | Q9Y2C2 | protein_coding | tolerated_low_confidence(0.6) | benign(0.027) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| UST | SNV | Missense_Mutation | rs772986508 | c.478G>A | p.Glu160Lys | p.E160K | Q9Y2C2 | protein_coding | tolerated(0.55) | benign(0.031) | TCGA-A2-A1FV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamide | SD |
| UST | SNV | Missense_Mutation | rs370896083 | c.31N>C | p.Gly11Arg | p.G11R | Q9Y2C2 | protein_coding | deleterious_low_confidence(0) | benign(0.058) | TCGA-GM-A2DH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | CR |
| UST | SNV | Missense_Mutation | novel | c.401N>C | p.Val134Ala | p.V134A | Q9Y2C2 | protein_coding | tolerated(0.27) | benign(0.246) | TCGA-PL-A8LZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
| UST | insertion | Nonsense_Mutation | novel | c.936_937insAGACTATTGTAGGTACTTAGTTGTTGGATGCAT | p.Pro312_Glu313insArgLeuLeuTerValLeuSerCysTrpMetHis | p.P312_E313insRLL*VLSCWMH | Q9Y2C2 | protein_coding | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| UST | SNV | Missense_Mutation | novel | c.433N>G | p.Thr145Ala | p.T145A | Q9Y2C2 | protein_coding | deleterious(0.04) | possibly_damaging(0.864) | TCGA-VS-A9V1-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| UST | SNV | Missense_Mutation | c.490N>G | p.Leu164Val | p.L164V | Q9Y2C2 | protein_coding | tolerated(0.14) | benign(0.137) | TCGA-A6-6141-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | 5-fu | SD | |
| UST | SNV | Missense_Mutation | c.1145C>T | p.Pro382Leu | p.P382L | Q9Y2C2 | protein_coding | deleterious_low_confidence(0.02) | benign(0.245) | TCGA-AA-A02R-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| UST | SNV | Missense_Mutation | rs746546399 | c.673N>T | p.Arg225Cys | p.R225C | Q9Y2C2 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-AD-5900-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 10090 | UST | NA | nortriptyline | NORTRIPTYLINE | 20360315,25916525 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |